Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aldeyra Therapeutics (ALDX)
NASDAQ:ALDX
RESEARCH TOOLSreports
Holding ALDX?
Track your performance easily
ALDX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.71 - $6.55
Previous CloseN/A
Volume102.94K
Average Volume (3M)416.43K
Market Cap
$279.88M
Enterprise Value$126.91M
Total Cash (Recent Filing)$24.91M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta2.62
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.75
Shares Outstanding59,549,600
10 Day Avg. Volume374,684
30 Day Avg. Volume416,427
Standard Deviation0.26
R-Squared0.08
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.45
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.96
Forecast
1Y Price Target
$10.75Price Target Upside124.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Aldeyra Therapeutics News
PremiumCompany Announcements
Aldeyra Therapeutics Announces Executive Team Changes
PremiumCompany Announcements
Aldeyra Therapeutics Announces Major Dry Eye Treatment Success
PremiumCompany Announcements
Aldeyra Therapeutics Completes Phase 3 Trial Enrollment for ReproxalapOwnership Overview
19.01% Insiders
11.31% Mutual Funds
0.61% Other Institutional Investors
60.12% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ALDX FAQ
What was Aldeyra Therapeutics’s price range in the past 12 months?
Aldeyra Therapeutics lowest stock price was $2.71 and its highest was $6.55 in the past 12 months.
What is Aldeyra Therapeutics’s market cap?
Aldeyra Therapeutics’s market cap is $279.88M.
When is Aldeyra Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aldeyra Therapeutics’s earnings last quarter?
Aldeyra Therapeutics released its earnings results on Mar 07, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.111 by $0.031.
Is Aldeyra Therapeutics overvalued?
According to Wall Street analysts Aldeyra Therapeutics’s price is currently Undervalued.
Does Aldeyra Therapeutics pay dividends?
Aldeyra Therapeutics does not currently pay dividends.
What is Aldeyra Therapeutics’s EPS estimate?
Aldeyra Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aldeyra Therapeutics have?
Aldeyra Therapeutics has 59,549,600 shares outstanding.
What happened to Aldeyra Therapeutics’s price movement after its last earnings report?
Aldeyra Therapeutics reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.111. Following the earnings report the stock price went up 0.238%.
Which hedge fund is a major shareholder of Aldeyra Therapeutics?
Among the largest hedge funds holding Aldeyra Therapeutics’s share is Perceptive Advisors LLC. It holds Aldeyra Therapeutics’s shares valued at 50M.
---
Aldeyra Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.75 (124.90% Upside)
$10.75 (124.90% Upside)
Blogger Sentiment
Bullish
ALDX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 500.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.9%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.17%
12-Months-Change
Fundamentals
Return on Equity
-43.05%
Trailing 12-Months
Asset Growth
-20.34%
Trailing 12-Months
Company Description
Aldeyra Therapeutics
Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.
---
ALDX Company Deck
---
ALDX Earnings Call
Q4 2023
0:00 / 0:00
---
ALDX Stock 12 Month Forecast
Average Price Target
$10.75
▲(124.90% Upside)
Technical Analysis
Atara Biotherapeutics
―
Corcept Therapeutics
―
Fate Therapeutics
―
Karyopharm Therapeutics
―
Seres Therapeutics
―
Viking Therapeutics
―
Best Analysts Covering ALDX
1 Year
1 Year Success Rate
9/15 ratings generated profit
1 Year Average Return
+36.98%
reiterated a buy rating 2 months ago
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +36.98% per trade.
---